Efficacy of pentoxifylline–tocopherol–clodronate in mandibular osteoradionecrosis

Objectives/Hypothesis PENTOCLO treatment, associating pentoxifylline, tocopherol, and clodronate, resolves radiation‐induced fibrosis. The main aim of the present study was to prospectively assess efficacy in mandibular osteoradionecrosis (ORN). Study Design Prospective cohort study. Methods Twenty‐...

Full description

Saved in:
Bibliographic Details
Published in:The Laryngoscope 2020-11, Vol.130 (11), p.E559-E566
Main Authors: Dissard, Alexis, P. Dang, Nathalie, Barthelemy, Isabelle, Delbet, Candice, Puechmaille, Mathilde, Depeyre, Arnaud, Pereira, Bruno, Martin, Fanny, Guillemin, Florent, Biau, Julian, Mirafzal, Sonia, Mom, Thierry, Gilain, Laurent, Saroul, Nicolas
Format: Article
Language:English
Subjects:
Aged
Aged, 80 and over
Bone Density Conservation Agents - therapeutic use
Bones
clodronate
Clodronic Acid - therapeutic use
Drug Combinations
Drug therapy
Female
Humans
Jaw
Life Sciences
Male
mandible
Mandibular Diseases - drug therapy
Middle Aged
Osteoradionecrosis
Osteoradionecrosis - drug therapy
pentoxifylline
Pentoxifylline - therapeutic use
Prospective Studies
Radiation therapy
tocopherol
Tocopherols - therapeutic use
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Objectives/Hypothesis PENTOCLO treatment, associating pentoxifylline, tocopherol, and clodronate, resolves radiation‐induced fibrosis. The main aim of the present study was to prospectively assess efficacy in mandibular osteoradionecrosis (ORN). Study Design Prospective cohort study. Methods Twenty‐seven patients with mandibular ORN were included in the Pentoclauvergne Study between January 2014 and February 2016. After an initial 28‐day phase of antibiotic, antifungal, and corticosteroid therapy, they received the PENTOCLO association daily until cure or a maximum of 24 months. The main assessment criterion was exposed bone area (EBA); secondary criteria comprised the Subjective, objective, management, and analytic (SOMA) score. Results Under PENTOCLO, EBA decreased by 28% at 2 months, 55% at 6 months, and 92% at 24 months; the SOMA score decreased by 23%, 38%, and 50%, respectively. A complete treatment course cured 76.5% of patients at a mean 9.6 months. Conclusions PENTOCLO is a simple, well‐tolerated, and effective treatment for mandibular ORN. Level of Evidence 4 Laryngoscope, 130:E559–E566, 2020
ISSN:0023-852X
1531-4995
DOI:10.1002/lary.28399